Race Oncology Limited (RAONF)

Race Oncology Limited (RAONF) Healthcare & Pipeline Overview

Race Oncology Limited, an Australian precision oncology firm, develops Zantrene, a potent FTO inhibitor, currently in Phase II/III clinical trials for multiple cancers including melanoma and acute myeloid leukaemia. The company leverages strategic research partnerships to advance its therapeutic pipeline and explore new formulations.

What Is the Investment Thesis for RAONF?

Race Oncology Limited presents an investment thesis centered on the clinical advancement and potential market penetration of its lead drug candidate, Zantrene. The drug, a potent FTO inhibitor, is currently in Phase II/III clinical trials for multiple oncology indications, including melanoma and acute myeloid leukaemia, representing significant market opportunities within precision oncology. Successful progression and positive data from these trials could serve as a major catalyst, validating Zantrene's unique mechanism of action and accelerating its path to commercialization. The company's strategic partnerships with academic institutions for preclinical research and formulation development further enhance its long-term pipeline potential. However, as an R&D-stage biotechnology company, RAONF carries inherent risks, evidenced by its significant negative profit margin of -1190.8% and a high beta of 1.91, indicating substantial volatility. Future funding requirements for clinical trials and commercialization efforts will be critical. Investors should monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure necessary capital to advance Zantrene through its development lifecycle.

Based on FMP financials and quantitative analysis

RAONF Key Highlights

• Market Capitalization of $451.73M, reflecting its valuation as a clinical-stage biotechnology company.
• Gross Margin of 49.8%, indicating a strong ability to cover direct costs once commercial operations commence.
• Profit Margin of -1190.8%, typical for a biotechnology firm in the R&D phase with no commercialized products generating revenue.
• Beta of 1.91, suggesting the stock is significantly more volatile than the broader market, consistent with early-stage biotech companies.
• Zantrene is in Phase II/III clinical trials for multiple cancer indications, representing a critical stage in its development pathway.

Who Are RAONF's Competitors?

RAONF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RAONF's Key Strengths?

• Lead drug candidate, Zantrene, is in advanced Phase II/III clinical trials for multiple cancer indications.
• Unique mechanism of action targeting the FTO protein, potentially offering a differentiated therapy.
• Strategic partnerships with academic institutions for ongoing research and formulation development.
• Existing clinical data for Zantrene (Bisantrene) may de-risk certain aspects of development.

What Are RAONF's Weaknesses?

• Significant negative profit margin (-1190.8%), typical for an R&D-stage company, indicating no current commercial revenue.
• High beta (1.91) suggests substantial stock price volatility and higher investment risk.
• Reliance on a single primary drug candidate (Zantrene) for its near-term value proposition.
• Trades on the OTC market, which can imply lower liquidity and potentially less stringent reporting requirements.

What Could Drive RAONF Stock Higher?

• Release of interim or final data from ongoing Phase II/III clinical trials for Zantrene in various cancer indications.
• Announcement of new strategic partnerships for Zantrene's development, commercialization, or formulation advancements.
• Progress in preclinical research with the University of Newcastle, potentially identifying new targets or applications for Zantrene.
• Advancements in formulation development with the University of Wollongong, leading to optimized drug delivery.

What Are the Key Risks for RAONF?

• Negative return on equity (-47.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of Zantrene to meet primary or secondary endpoints in ongoing Phase II/III clinical trials.
• Significant negative profit margin (-1190.8%) indicating continued reliance on external funding to sustain operations.
• Regulatory setbacks or delays in obtaining marketing approval for Zantrene from health authorities.
• High stock price volatility (Beta 1.91) inherent to early-stage biotechnology companies and OTC listing.
• Increased competition from other pharmaceutical companies developing oncology treatments, including FTO inhibitors or similar epigenetic therapies.

What Are the Growth Opportunities for RAONF?

• Growth opportunity 1: Successful completion and positive data from ongoing Phase II/III clinical trials for Zantrene. The current trials cover significant cancer types such as melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. Positive outcomes, particularly demonstrating superior efficacy or safety profiles compared to existing treatments, would be a major catalyst. This could lead to accelerated regulatory pathways and market approval, unlocking access to multi-billion dollar oncology markets. The timeline for these opportunities is directly tied to clinical trial progression and regulatory review cycles, potentially within the next 2-5 years.
• Growth opportunity 2: Expansion of Zantrene into additional cancer indications or therapeutic areas. As a potent FTO inhibitor, Zantrene's mechanism of action may have broader applicability beyond the currently investigated cancers. Preclinical research, such as the program with the University of Newcastle, could identify new targets or synergistic combinations, leading to new clinical programs. Each new indication represents a distinct market opportunity, potentially adding hundreds of millions to billions of dollars in addressable market size. This long-term opportunity could unfold over a 5-10 year horizon as new research translates into clinical trials.
• Growth opportunity 3: Development and commercialization of new Zantrene formulations. The strategic partnership with the University of Wollongong focuses on assessing various formulations of the drug. Improved formulations could enhance drug delivery, bioavailability, reduce side effects, or enable new routes of administration, thereby broadening Zantrene's utility and patient acceptance. For instance, an oral formulation could significantly improve patient convenience and adherence compared to intravenous options. Such advancements could expand market reach and improve competitive positioning within existing and future indications, with development timelines typically ranging from 3-7 years.
• Growth opportunity 4: Strategic partnerships for global commercialization and distribution. As Zantrene progresses through clinical development, Race Oncology may seek to partner with larger pharmaceutical companies for late-stage development, regulatory approval, and commercialization in major global markets. Such partnerships can provide significant non-dilutive funding, leverage established sales and marketing infrastructure, and accelerate market penetration. The oncology drug market is global, and a successful partnership could unlock access to markets in North America, Europe, and Asia, which collectively represent hundreds of billions in annual sales. These opportunities could materialize as Zantrene approaches Phase III completion or regulatory submission.
• Growth opportunity 5: Leveraging preclinical research to identify new drug candidates or targets. The ongoing preclinical research program with the University of Newcastle is crucial for understanding Zantrene's full potential and identifying novel applications or even entirely new drug candidates based on FTO inhibition or related pathways. Success in this area could lead to a diversified pipeline beyond Zantrene, reducing reliance on a single asset and creating multiple shots on goal. This long-term strategy, while inherently high-risk, could yield significant returns by addressing unmet medical needs in oncology, with new drug discovery timelines typically spanning 10+ years from concept to market.

What Opportunities Does RAONF Have?

• Successful completion of Phase II/III clinical trials leading to regulatory approval and market entry for Zantrene.
• Expansion of Zantrene into new cancer indications or therapeutic areas based on ongoing preclinical research.
• Development of improved Zantrene formulations to enhance efficacy, safety, or patient convenience.
• Formation of strategic commercialization partnerships with larger pharmaceutical companies for global market access.

What Threats Does RAONF Face?

• Failure of Zantrene in clinical trials or inability to meet primary endpoints.
• Intense competition from other oncology drug developers, including established pharmaceutical giants.
• Regulatory hurdles and delays in obtaining marketing approvals for Zantrene.
• Need for significant future funding to complete clinical trials and commercialize Zantrene, potentially leading to shareholder dilution.
• Market acceptance challenges if Zantrene's efficacy or safety profile is not compelling enough against existing standards of care.

What Are RAONF's Competitive Advantages?

• Proprietary drug candidate Zantrene with a unique mechanism of action as an FTO inhibitor.
• Existing clinical data for Zantrene, potentially accelerating development timelines compared to de novo drug discovery.
• Strategic research partnerships with academic institutions (University of Newcastle, University of Wollongong) for preclinical and formulation development.
• Specialized focus on precision oncology and epigenetic targets, offering a differentiated approach in the cancer treatment landscape.

What Does RAONF Do?

Based in Sydney, Australia, Race Oncology Limited is an Australian precision oncology firm that commenced operations in 2011. The company's core mission is centered on the development and commercialization of Zantrene (bisantrene dihydrochloride), a small molecule therapeutic agent with a unique mechanism of action. Zantrene functions as a potent inhibitor of the fatso/fat mass and obesity associated protein (FTO), a key epigenetic regulator implicated in various oncogenic pathways. This targeted approach positions Zantrene as a potential treatment for a range of difficult-to-treat cancers. Currently, Zantrene is progressing through Phase II/III clinical trials, evaluating its efficacy and safety across multiple cancer types, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. Beyond its active clinical development, Race Oncology is deeply committed to foundational research, fostering a robust preclinical program with the University of Newcastle to further investigate Zantrene's therapeutic potential and explore novel applications. Additionally, the company maintains a strategic partnership with the University of Wollongong, focusing on assessing various formulations of the drug to optimize delivery and patient outcomes. This dual focus on clinical advancement and preclinical innovation underscores Race Oncology's strategy to maximize Zantrene's value. The company underwent a significant corporate evolution, initially operating as Coronado Resources Limited before rebranding and adopting its current name, Race Oncology Limited, in July 2016, signaling its dedicated pivot towards oncology drug development.

What Products and Services Does RAONF Offer?

• Develop Zantrene, a small molecule drug targeting the FTO protein.
• Conduct Phase II/III clinical trials for Zantrene in various cancers like melanoma, acute myeloid leukaemia, and ovarian cancer.
• Engage in preclinical research with the University of Newcastle to explore Zantrene's therapeutic potential.
• Partner with the University of Wollongong to assess new formulations of Zantrene.
• Focus on precision oncology, aiming for targeted cancer treatments.
• Operate as an Australian biotechnology company with a global development outlook.

How Does RAONF Make Money?

• Primarily an R&D-focused biotechnology company, investing in the clinical development of Zantrene.
• Future revenue generation is anticipated through the commercialization of Zantrene, either independently or via licensing agreements with larger pharmaceutical partners.
• Potential for milestone payments and royalties from future partnerships related to Zantrene's development and sales.
• Currently reliant on capital raises and grants to fund ongoing research and clinical trial expenses.

What Industry Does RAONF Operate In?

Race Oncology Limited operates within the dynamic and high-growth biotechnology industry, specifically focusing on precision oncology. The global oncology market is projected to continue expanding significantly, driven by an aging population, increasing cancer incidence, and advancements in targeted therapies. Race Oncology's focus on Zantrene, an FTO inhibitor, positions it within the emerging field of epigenetic oncology, which seeks to target the mechanisms that control gene expression in cancer cells. This niche offers potential for differentiated therapies compared to traditional chemotherapy or broad-spectrum targeted agents. The competitive landscape is intense, with numerous pharmaceutical and biotechnology companies vying for market share in various cancer indications. However, Zantrene's unique mechanism of FTO inhibition could provide a competitive advantage, particularly for cancers where FTO plays a critical role. The company's progress through Phase II/III clinical trials is crucial for establishing its position and demonstrating efficacy against established and investigational treatments.

Who Are RAONF's Key Customers?

• Ultimately, patients suffering from cancers such as melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer.
• In the future, oncologists and healthcare providers who would prescribe Zantrene.
• Potential pharmaceutical partners interested in licensing or acquiring Zantrene for broader market access.

Company Profile

Race Oncology Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sydney, AU. The company is led by CEO Daniel Tillett. RAONF has traded publicly since 2021.

ROE -47%Key Financial Metrics

Return on equity for Race Oncology Limited stands at -47.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.4%, the inverse of the P/E and a quick read on earnings relative to price.

RAONF Valuation & Market Position

With a $451.73M market cap, Race Oncology Limited sits in the small-cap segment of the market. Relative to its peer group, RAONF's quantitative score of 62/100 is below the peer average of 76/100.

Quarterly Financial Performance: Race Oncology Limited

Revenue for Race Oncology Limited came in at $788K during Q2 2025, a 85.0% contraction versus the preceding quarter. The company recorded a net loss of $5.3M, with diluted EPS of $-0.03. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare.

F-Score 2/9Financial Health

Race Oncology Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

FY2026 estForward Outlook

Wall Street analysts project Race Oncology Limited revenue of about $3.0M for fiscal 2026, with EPS near $-0.04.

RAONF Financials

RAONF Latest News

No recent news available for RAONF.

RAONF Analyst Consensus

RAONF MoonshotScore

RAONF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources